154 related articles for article (PubMed ID: 27055871)
41. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
Hird AW; Tron AE
Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
[TBL] [Abstract][Full Text] [Related]
42. T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.
Hilmenyuk T; Ruckstuhl CA; Hayoz M; Berchtold C; Nuoffer JM; Solanki S; Keun HC; Beavis PA; Riether C; Ochsenbein AF
Oncoimmunology; 2017; 7(1):e1365997. PubMed ID: 29296517
[TBL] [Abstract][Full Text] [Related]
43. Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation.
Lindner SE; Wissler M; Gründer A; Aumann K; Ottina E; Peintner L; Brauns-Schubert P; Preiss F; Herzog S; Borner C; Charvet C; Villunger A; Pahl HL; Maurer U
Oncogene; 2014 Oct; 33(44):5221-4. PubMed ID: 24213575
[TBL] [Abstract][Full Text] [Related]
44. Functional profiling to improve therapy in TCL.
Elenitoba-Johnson KSJ
Blood; 2019 Feb; 133(6):504-506. PubMed ID: 30733202
[No Abstract] [Full Text] [Related]
45. Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016.
Blood Adv; 2022 Apr; 6(8):2548. PubMed ID: 35446384
[No Abstract] [Full Text] [Related]
46. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A; Szlavik Z; Murray J; Davidson J; Maragno AL; Le Toumelin-Braizat G; Chanrion M; Kelly GL; Gong JN; Moujalled DM; Bruno A; Csekei M; Paczal A; Szabo ZB; Sipos S; Radics G; Proszenyak A; Balint B; Ondi L; Blasko G; Robertson A; Surgenor A; Dokurno P; Chen I; Matassova N; Smith J; Pedder C; Graham C; Studeny A; Lysiak-Auvity G; Girard AM; Gravé F; Segal D; Riffkin CD; Pomilio G; Galbraith LC; Aubrey BJ; Brennan MS; Herold MJ; Chang C; Guasconi G; Cauquil N; Melchiore F; Guigal-Stephan N; Lockhart B; Colland F; Hickman JA; Roberts AW; Huang DC; Wei AH; Strasser A; Lessene G; Geneste O
Nature; 2016 Oct; 538(7626):477-482. PubMed ID: 27760111
[TBL] [Abstract][Full Text] [Related]
47. CD1d-restricted peripheral T cell lymphoma in mice and humans.
Bachy E; Urb M; Chandra S; Robinot R; Bricard G; de Bernard S; Traverse-Glehen A; Gazzo S; Blond O; Khurana A; Baseggio L; Heavican T; Ffrench M; Crispatzu G; Mondière P; Schrader A; Taillardet M; Thaunat O; Martin N; Dalle S; Le Garff-Tavernier M; Salles G; Lachuer J; Hermine O; Asnafi V; Roussel M; Lamy T; Herling M; Iqbal J; Buffat L; Marche PN; Gaulard P; Kronenberg M; Defrance T; Genestier L
J Exp Med; 2016 May; 213(5):841-57. PubMed ID: 27069116
[TBL] [Abstract][Full Text] [Related]
48. An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles.
Kueh AJ; Pal M; Tai L; Liao Y; Smyth GK; Shi W; Herold MJ
Cell Death Differ; 2017 Oct; 24(10):1821-1822. PubMed ID: 28753205
[No Abstract] [Full Text] [Related]
49. Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability.
Zain J; Kallam A
Front Oncol; 2023; 13():1150715. PubMed ID: 37188189
[TBL] [Abstract][Full Text] [Related]
50. Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Vitale I; Pietrocola F; Guilbaud E; Aaronson SA; Abrams JM; Adam D; Agostini M; Agostinis P; Alnemri ES; Altucci L; Amelio I; Andrews DW; Aqeilan RI; Arama E; Baehrecke EH; Balachandran S; Bano D; Barlev NA; Bartek J; Bazan NG; Becker C; Bernassola F; Bertrand MJM; Bianchi ME; Blagosklonny MV; Blander JM; Blandino G; Blomgren K; Borner C; Bortner CD; Bove P; Boya P; Brenner C; Broz P; Brunner T; Damgaard RB; Calin GA; Campanella M; Candi E; Carbone M; Carmona-Gutierrez D; Cecconi F; Chan FK; Chen GQ; Chen Q; Chen YH; Cheng EH; Chipuk JE; Cidlowski JA; Ciechanover A; Ciliberto G; Conrad M; Cubillos-Ruiz JR; Czabotar PE; D'Angiolella V; Daugaard M; Dawson TM; Dawson VL; De Maria R; De Strooper B; Debatin KM; Deberardinis RJ; Degterev A; Del Sal G; Deshmukh M; Di Virgilio F; Diederich M; Dixon SJ; Dynlacht BD; El-Deiry WS; Elrod JW; Engeland K; Fimia GM; Galassi C; Ganini C; Garcia-Saez AJ; Garg AD; Garrido C; Gavathiotis E; Gerlic M; Ghosh S; Green DR; Greene LA; Gronemeyer H; Häcker G; Hajnóczky G; Hardwick JM; Haupt Y; He S; Heery DM; Hengartner MO; Hetz C; Hildeman DA; Ichijo H; Inoue S; Jäättelä M; Janic A; Joseph B; Jost PJ; Kanneganti TD; Karin M; Kashkar H; Kaufmann T; Kelly GL; Kepp O; Kimchi A; Kitsis RN; Klionsky DJ; Kluck R; Krysko DV; Kulms D; Kumar S; Lavandero S; Lavrik IN; Lemasters JJ; Liccardi G; Linkermann A; Lipton SA; Lockshin RA; López-Otín C; Luedde T; MacFarlane M; Madeo F; Malorni W; Manic G; Mantovani R; Marchi S; Marine JC; Martin SJ; Martinou JC; Mastroberardino PG; Medema JP; Mehlen P; Meier P; Melino G; Melino S; Miao EA; Moll UM; Muñoz-Pinedo C; Murphy DJ; Niklison-Chirou MV; Novelli F; Núñez G; Oberst A; Ofengeim D; Opferman JT; Oren M; Pagano M; Panaretakis T; Pasparakis M; Penninger JM; Pentimalli F; Pereira DM; Pervaiz S; Peter ME; Pinton P; Porta G; Prehn JHM; Puthalakath H; Rabinovich GA; Rajalingam K; Ravichandran KS; Rehm M; Ricci JE; Rizzuto R; Robinson N; Rodrigues CMP; Rotblat B; Rothlin CV; Rubinsztein DC; Rudel T; Rufini A; Ryan KM; Sarosiek KA; Sawa A; Sayan E; Schroder K; Scorrano L; Sesti F; Shao F; Shi Y; Sica GS; Silke J; Simon HU; Sistigu A; Stephanou A; Stockwell BR; Strapazzon F; Strasser A; Sun L; Sun E; Sun Q; Szabadkai G; Tait SWG; Tang D; Tavernarakis N; Troy CM; Turk B; Urbano N; Vandenabeele P; Vanden Berghe T; Vander Heiden MG; Vanderluit JL; Verkhratsky A; Villunger A; von Karstedt S; Voss AK; Vousden KH; Vucic D; Vuri D; Wagner EF; Walczak H; Wallach D; Wang R; Wang Y; Weber A; Wood W; Yamazaki T; Yang HT; Zakeri Z; Zawacka-Pankau JE; Zhang L; Zhang H; Zhivotovsky B; Zhou W; Piacentini M; Kroemer G; Galluzzi L
Cell Death Differ; 2023 May; 30(5):1097-1154. PubMed ID: 37100955
[TBL] [Abstract][Full Text] [Related]
51. Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression.
Sumarni U; Zhu J; Sinnberg T; Eberle J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293331
[TBL] [Abstract][Full Text] [Related]
52. The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine.
Ferrarini I; Rigo A; Visco C
Haematologica; 2022 Apr; 107(4):790-802. PubMed ID: 35045693
[TBL] [Abstract][Full Text] [Related]
53. Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy.
Xu Q; Li T; Chen H; Kong J; Zhang L; Yin H
RSC Med Chem; 2021 Oct; 12(10):1771-1779. PubMed ID: 34778778
[TBL] [Abstract][Full Text] [Related]
54. Physiological Functions of Mcl-1: Insights From Genetic Mouse Models.
Chin HS; Fu NY
Front Cell Dev Biol; 2021; 9():704547. PubMed ID: 34336857
[TBL] [Abstract][Full Text] [Related]
55. Updates in the Treatment of Peripheral T-Cell Lymphomas.
Saleh K; Michot JM; Ribrag V
J Exp Pharmacol; 2021; 13():577-591. PubMed ID: 34188559
[TBL] [Abstract][Full Text] [Related]
56. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Epstein-Peterson ZD; Horwitz SM
Semin Hematol; 2021 Apr; 58(2):78-84. PubMed ID: 33906725
[TBL] [Abstract][Full Text] [Related]
57. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
58. Enhancing venetoclax activity in hematological malignancies.
Satta T; Grant S
Expert Opin Investig Drugs; 2020 Jul; 29(7):697-708. PubMed ID: 32600066
[TBL] [Abstract][Full Text] [Related]
59. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Maurer B; Nivarthi H; Wingelhofer B; Pham HTT; Schlederer M; Suske T; Grausenburger R; Schiefer AI; Prchal-Murphy M; Chen D; Winkler S; Merkel O; Kornauth C; Hofbauer M; Hochgatterer B; Hoermann G; Hoelbl-Kovacic A; Prochazkova J; Lobello C; Cumaraswamy AA; Latzka J; Kitzwögerer M; Chott A; Janikova A; Pospíšilova Š; Loizou JI; Kubicek S; Valent P; Kolbe T; Grebien F; Kenner L; Gunning PT; Kralovics R; Herling M; Müller M; Rülicke T; Sexl V; Moriggl R
Haematologica; 2020; 105(2):435-447. PubMed ID: 31123029
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
